{
    "clinical_study": {
        "@rank": "46947", 
        "acronym": "THRIVE", 
        "brief_summary": {
            "textblock": "THRIVE is an observational study that will collect information on patients with UCDs. THRIVE\n      will follow enrolled participants for up to 10 years. As an observational study, enrolled\n      patients will not be required to make any additional office visits or take any medicine\n      outside of normal care."
        }, 
        "brief_title": "Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)", 
        "completion_date": {
            "#text": "September 2026", 
            "@type": "Anticipated"
        }, 
        "condition": "Urea Cycle Disorder", 
        "condition_browse": {
            "mesh_term": "Urea Cycle Disorders, Inborn"
        }, 
        "detailed_description": {
            "textblock": "UCDs disproportionately affect children and females: depending on the severity of the\n      defect, a UCD can manifest shortly after birth or later in life. This study will track\n      long-term outcomes in UCD patients and effects of ammonia-scavenging agents on\n      neuropsychological functions of UCD patients.\n\n      This is a non-interventional, multi-center registry to be conducted in patients with UCDs.\n      Investigators will prescribe treatments based on usual clinical practice, and there will be\n      no restrictions on the use of commercially available medications. As an observational study,\n      this study will not change the patient/ healthcare provider relationship, nor influence the\n      healthcare provider's drug prescription or the therapeutic management of the patient.\n\n      Patients with UCDs will be recruited and invited to attend a Baseline visit. After eligible\n      patients are enrolled, retrospective and baseline data will be collected. Patients will be\n      followed for up to 10 years, during which time they will be assessed by their healthcare\n      provider. Patients and healthcare provider will be asked to report episodes of\n      hyperammonemic crisis, available ammonia values, and other information."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed or suspected diagnosis of UCD\n\n          -  Signed informed consent/Health Insurance Portability and Accountability Act (HIPAA)\n             Authorization and medical records release\n\n        Exclusion Criteria:\n\n          -  Any other reason that, in the Investigator's opinion, makes the patient unsuitable to\n             participate in this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with a confirmed or suspected diagnosis of UCD"
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948427", 
            "org_study_id": "HPN-100-014"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "UCD", 
            "BUPHENYL", 
            "RAVICTI", 
            "Urea", 
            "Urea cycle disorder", 
            "Glycerol phenylbutyrate", 
            "Benzoate", 
            "Sodium phenylbutyrate", 
            "Ornithine transcarbamylase (OTC)", 
            "Argininosuccinate synthetase (ASS)", 
            "Argininosuccinate lyase (ASL)", 
            "Carbamyl phosphate synthetase (CPS)", 
            "Arginine", 
            "Citrulline", 
            "Ammonia"
        ], 
        "lastchanged_date": "September 18, 2013", 
        "link": {
            "description": "THRIVE Registry Website", 
            "url": "https://www.thriveregistry.com/index.html"
        }, 
        "location": {
            "contact": {
                "email": "thriveregistry@unitedbiosource.com", 
                "last_name": "THRIVE Registry Team", 
                "phone": "855-823-2595"
            }, 
            "facility": {
                "address": {
                    "city": "Blue Bell", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19422"
                }, 
                "name": "United BioSource Corporation"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Long-Term Registry of Patients With Urea Cycle Disorders (UCDs)", 
        "overall_contact": {
            "email": "thriveregistry@unitedbiosource.com", 
            "last_name": "United Biosource Corporation", 
            "phone": "855-UCD-2595"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2026", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of:\nBlood chemistry, neurocognitive outcomes, growth and development and medications related to the management of UCD", 
            "measure": "Assessment of UCD specific disease characteristics", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for the duration of the registry. The expected duration is 10 years."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948427"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hyperion Therapeutics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hyperion Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "10 Years", 
        "verification_date": "September 2013"
    }
}